Sage Therapeutic Com (SAGE) Stock Price, Quote & News

Company Profile

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies;...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 299 8380

Fax: 617 299 8379

Website: www.sagerx.com

Address:

55 Cambridge Parkway, Cambridge, United States

JarvisFlow Jul. 14 at 11:00 AM

Canaccord Genuity has adjusted their stance on Sage Therapeutics ( $SAGE ), setting the rating to Hold with a target price of 17 → 9.

0 · Reply

buyandsold Jul. 13 at 5:06 PM

I expect $BIIB to offer 25 cents more cash and the same CVR terms as $SUPN to take $SAGE I think that if the try to value the CVR and do all cash then $SAGE management hates them so much they will say the CVR is worth more and reject. If $BIIB does not make an offer this weekend my expectation will be much reduced as time is really rather short to make a move.

0 · Reply

BiotechBonesaw Jul. 8 at 5:15 PM

$ALT this isn’t how the big pharma M&A game is played. At a high level: If the board gets an offer then they have to shop around and then disclose it either way within 3 days. Sometimes that’s the only one at first - a la $SAGE with $BIIB (Biogen made them a lowball offer before Supernus ultimately bought them out for 60% more than what Biogen offered). If they are in negotiations then we shouldn’t hear shit. And if we do hear something then 90%+ odds its bullshit. And BD negotiations are frankly the only excuse for Viper Garg not buying back shares like $TNXP CEO Seth Leader Man just did, or $NUVB CEO Hung always has 💪

0 · Reply

anachartanalyst Jul. 8 at 2:02 PM

$SAGE https://anachart.com/wp-content/uploads/ana_temp/1751983314_soc-img.jpg

0 · Reply

JarvisFlow Jul. 8 at 1:00 PM

Scotiabank has updated their rating for Sage Therapeutics ( $SAGE ) to Sector Perform with a price target of 9.2.

0 · Reply

RonIsWrong Jul. 3 at 10:04 PM

$SAGE $XBI Sage talked to 43 'counterparties' before inking Supernus deal

2 · Reply

shay7557 Jul. 3 at 7:18 PM

$SGMO Anyone read the Endpoints article on $SAGE this morning ? Sage met with 43 potential parties before signing a deal. Tough business landscape currently.

0 · Reply

amazingcrwns Jul. 2 at 5:05 PM

$SAGE Thinking of picking up a small position in my roth account. I'd obviously take a small hit if the deal goes through as proposed, and the CVR's never hit. BioGen might top the deal, or if the CVR's payout, I'd be ahead. The worst-case scenario (aside from the deal falling apart entirely) is paying for the experience. With Zurzuvae as the only oral PPD drug on the market and Lipocine's Brlizio still about 2 years away, the revenue targets are high but not out of reach if Supernus can get some momentum.

1 · Reply

11thestate Jul. 1 at 3:38 PM

$SAGE stockholders filed a claim against Sage Therapeutics for allegedly misleading investors about its drug pipeline, including zuranolone, and the chances of FDA approval. You can join this case to be notified about any new information: https://11th.com/cases/sage-investor-suit

0 · Reply

DonCorleone77 Jul. 1 at 1:30 PM

$SAGE $SUPN Sage Therapeutics cutting over 330 jobs, Boston Globe reports Sage Therapeutics (SAGE) is laying off most of its employees after announcing its planned acquisition earlier this month, The Boston Globe's Marin Wolf reports. The company will cut 338 jobs effective August 22, according to the report. Sage announced earlier this month that it will be acquired by Supernus Pharmaceuticals (SUPN) in a deal that could be worth up to $795M.

0 · Reply

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

SUPN

Jun 23, 2025, 7:59 AM EDT - 22 days ago

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

PHAT

Jun 17, 2025, 2:22 PM EDT - 4 weeks ago

These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News

Jun 17, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect

Jun 17, 2025, 8:31 AM EDT - 4 weeks ago

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

RGC VERV

Jun 16, 2025, 5:31 PM EDT - 4 weeks ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.

SUPN

Jun 16, 2025, 7:42 AM EDT - 4 weeks ago

Sage Therapeutics Stock Soars 35% After Sale to Supernus. What We Know.

Jun 16, 2025, 7:14 AM EDT - 4 weeks ago

Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal

SUPN

Jun 15, 2025, 10:00 AM EDT - 4 weeks ago

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jun 12, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Stockholders to Learn More About the Investigation

Jun 10, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Investors to Inquire about Securities Investigation

Jun 9, 2025, 8:30 AM EDT - 5 weeks ago

INVESTOR NOTICE: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. and Encourages Long-Term Investors to Contact the Firm - SAGE

Jun 8, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation

Jun 5, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Connect

Jun 3, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out

Jun 1, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation

May 29, 2025, 10:05 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities Investigation

May 27, 2025, 10:00 AM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the Investigation

May 25, 2025, 10:00 AM EDT - 7 weeks ago

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 22, 2025, 10:00 AM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Connect

May 18, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Reach Out

May 1, 2025, 10:00 AM EDT - 2 months ago

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 29, 2025, 10:33 PM EDT - 2 months ago

Sage Therapeutics, Inc. (SAGE) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 4:05 PM EDT - 2 months ago

Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates

Apr 9, 2025, 5:34 AM EDT - 3 months ago

Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag

BIIB

Apr 6, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Reach Out

Mar 4, 2025, 4:15 PM EST - 4 months ago

Sage Therapeutics Announces R&D Leadership Transition

Feb 11, 2025, 9:29 PM EST - 5 months ago

Sage Therapeutics, Inc. (SAGE) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 4:05 PM EST - 5 months ago

Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates

Jan 28, 2025, 4:30 PM EST - 6 months ago

Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Jan 27, 2025, 9:20 AM EST - 6 months ago

Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen's Unsolicited Acquisition Proposal

Jan 13, 2025, 10:40 AM EST - 6 months ago

Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid

BIIB

Jan 13, 2025, 9:38 AM EST - 6 months ago

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?

Jan 13, 2025, 7:24 AM EST - 6 months ago

Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen

BIIB

Jan 12, 2025, 6:00 PM EST - 6 months ago

Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference

Jan 10, 2025, 6:49 PM EST - 6 months ago

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen

BIIB

Jan 8, 2025, 6:30 AM EST - 6 months ago

Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025

Nov 26, 2024, 7:00 AM EST - 8 months ago

Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 10:36 AM EST - 8 months ago

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder

Nov 20, 2024, 7:34 AM EST - 8 months ago

Sage Therapeutics to end Huntington's disease trial after key therapy fails again

Nov 20, 2024, 6:58 AM EST - 8 months ago

Sage Therapeutics scraps development of rare disease drug after it fails mid-stage study

Nov 20, 2024, 6:30 AM EST - 8 months ago

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease

Oct 29, 2024, 9:35 PM EDT - 9 months ago

Sage Therapeutics, Inc. (SAGE) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 4:05 PM EDT - 9 months ago

Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates

JarvisFlow Jul. 14 at 11:00 AM

Canaccord Genuity has adjusted their stance on Sage Therapeutics ( $SAGE ), setting the rating to Hold with a target price of 17 → 9.

0 · Reply

buyandsold Jul. 13 at 5:06 PM

0 · Reply

BiotechBonesaw Jul. 8 at 5:15 PM

0 · Reply

anachartanalyst Jul. 8 at 2:02 PM

$SAGE https://anachart.com/wp-content/uploads/ana_temp/1751983314_soc-img.jpg

0 · Reply

JarvisFlow Jul. 8 at 1:00 PM

Scotiabank has updated their rating for Sage Therapeutics ( $SAGE ) to Sector Perform with a price target of 9.2.

0 · Reply

RonIsWrong Jul. 3 at 10:04 PM

$SAGE $XBI Sage talked to 43 'counterparties' before inking Supernus deal

2 · Reply

shay7557 Jul. 3 at 7:18 PM

$SGMO Anyone read the Endpoints article on $SAGE this morning ? Sage met with 43 potential parties before signing a deal. Tough business landscape currently.

0 · Reply

amazingcrwns Jul. 2 at 5:05 PM

1 · Reply

11thestate Jul. 1 at 3:38 PM

0 · Reply

DonCorleone77 Jul. 1 at 1:30 PM

0 · Reply

buyandsold Jun. 28 at 6:54 PM

$SAGE i sold 2 weeks ago and just bought back at 15 cents more as I believe a topping bid is coming.

0 · Reply

StocktwitsNews Jun. 23 at 2:54 AM

Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms $SAGE $SUPN $BIIB https://stocktwits.com/news/equity/markets/sage-therapeutics-stock-jp-morgan-sees-8-downside-after-supernus-buyout-terms/chmP8riRR55

0 · Reply

DonCorleone77 Jun. 22 at 8:25 PM

$SAGE Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan JPMorgan analyst Anupam Rama lowered the firm's price target on Sage Therapeutics to $8.50 from $11 and keeps a Neutral rating on the shares. The firm cites the acquisition deal price by Supernus Pharmaceuticals for the target cut.

0 · Reply

anachartanalyst Jun. 20 at 8:01 PM

$SAGE https://anachart.com/wp-content/uploads/ana_temp/1750449706_soc-img.jpg

0 · Reply

Rage_Against_The_Machine Jun. 19 at 8:13 PM

Halper Sadeh investigates $SAGE's $8.50+$3.50 CVR sale to Supernus. While the deal offers exit liquidity, Sage's fundamentals remain shaky: Q1 revenue still 84% below 2023 levels, burning $81.7M cash. Market pricing assumes flawless deal execution - law firm scrutiny suggests potential turbulence ahead. https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-verv-sage-ctlp-colb-on-behalf-of-shareholders-302486497.html

0 · Reply

Unicorn2020 Jun. 17 at 10:20 PM

$SUPN A major competitor of $VNDA just paid approximately $795 million to $SAGE, about $12/share for its new depression drug, Zurzuvae - the first and only oral treatment for postpartum depression. Note that SAGE has $6.77/share of cash-in-hand and $0 debt. The CEO of VANDA, Mihael H. Polymeropoulos wants a better offer than $12? That's not going to happen "IF" he keeps throwing the company cash away on silly ads and new employee hirings. Stop the frivolous spending, egg head!

1 · Reply

ZacksResearch Jun. 17 at 6:50 PM

$SAGE getting scooped up in $795 million deal — is this SUPN’s breakout moment? SUPN is acquiring Sage Therapeutics and locking down rights to depression drug Zurzuvae, signaling a bold push into neuroscience. Full deal breakdown here 👉 https://www.zacks.com/stock/news/2507455/sage-to-be-acquired-by-supernus-pharmaceuticals-in-795-million-deal?cid=sm-stocktwits-2-2507455-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2507455_TEASER

0 · Reply

ZacksResearch Jun. 17 at 5:47 PM

$SAGE surges 35.4% on acquisition news! 🚀 Supernus Pharmaceuticals is set to acquire Sage Therapeutics at $8.50/share, with a potential total value of $12/share if sales milestones are hit through a contingent value right. This acquisition will grant $SUPN rights to SAGE’s new depression drug, Zurzuvae, boosting its diverse neuroscience portfolio. Discover the full deal details here 👉 https://www.zacks.com/commentary/2507455/sage-to-be-acquired-by-supernus-pharmaceuticals-in-795-million-deal?cid=sm-stocktwits-2-2507455-body&ADID=SYND_STOCKTWITS_TWEET_2_2507455_BODY

0 · Reply

JarvisFlow Jun. 17 at 2:40 PM

Truist Securities updates rating for Sage Therapeutics ( $SAGE ) to Hold, target set at 8 → 9.

0 · Reply

JarvisFlow Jun. 17 at 2:18 PM

HC Wainwright & Co. has adjusted their stance on Sage Therapeutics ( $SAGE ), setting the rating to Neutral with a target price of 12.

0 · Reply

Thestocktraderhubzee Jun. 17 at 2:17 PM

$SAGE HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $12 Price Target

0 · Reply

JarvisFlow Jun. 17 at 12:30 PM

Canaccord Genuity has adjusted their stance on Sage Therapeutics ( $SAGE ), setting the rating to Hold with a target price of 8 → 8.5.

0 · Reply

Market Cap	572.98M
Revenue (ttm)	41.24M
Net Income (ttm)	-400.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-971.56%
Debt to Equity Ratio	0.00

Volume	1,068,300
Avg Vol	1,811,582
Day's Range	N/A - N/A
Shares Out	62.62M
Stochastic %K	37%
Beta	0.29
Analysts	Hold
Price Target	$8.14